Blake Baird
Family Medicine · Perry, OKNPI 1982607743
Payments from drug & device makers
Across 83 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$278
- Lilly USA, LLC$256
- Bayer$236
- AstraZeneca$229
- Pfizer$90
- Astellas Pharma US Inc$80
- plus $280 from 14 others
What the payments were for
- Food & beverage$1,448100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 16 | $278 |
| Lilly USA, LLC | 16 | $256 |
| Bayer | 12 | $236 |
| AstraZeneca | 13 | $229 |
| Pfizer | 6 | $90 |
| Astellas Pharma US Inc | 3 | $80 |
| Ultragenyx Pharmaceutical Inc. | 2 | $37 |
| Johnson & Johnson | 2 | $36 |
| Boehringer Ingelheim | 2 | $25 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Amgen | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Merck | 1 | $16 |
| Biogen | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
| Nabriva Therapeutics, PLC | 1 | $13 |
| GSK | 1 | $13 |
How this compares
$1,448 in reported general payments places this provider in the 65th percentile of 1,730 family medicine providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 38 | $45,538 |
| OzempicSemaglutide | 45 | $42,567 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 94 | $38,975 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $28,361 |
| EliquisApixaban | 36 | $26,993 |
| FarxigaDapagliflozin Propanediol | 34 | $25,662 |
| JanumetSitagliptin Phos/Metformin Hcl | 40 | $24,703 |
| JanuviaSitagliptin Phosphate | 14 | $6,983 |
| InvokanaCanagliflozin | 12 | $6,968 |
| JardianceEmpagliflozin | 12 | $6,944 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $2,923 |
| Metoprolol Succinate | 132 | $2,415 |
| Atorvastatin Calcium | 222 | $2,308 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $2,194 |
| DilantinPhenytoin Sodium Extended | 12 | $1,772 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanumet Xr, Janumet, Januvia | $16 | $70,661148 claims |
| Lilly USA, LLCTrulicity | $256 | $45,53838 claims |
| Novo NordiskOzempic | $278 | $42,56745 claims |
| PfizerEliquis, Dilantin | $90 | $28,76448 claims |
| AstraZenecaFarxiga, Symbicort | $229 | $28,58447 claims |
| Johnson & JohnsonInvokana | $36 | $6,96812 claims |
| Boehringer IngelheimJardiance | $25 | $6,94412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Perry
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.